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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does 
erythropoietin prevent neurodevelopmental symptoms in neonates with hypoxic ischemic 
encephalopathy?” 
 
STUDY DESIGN: A systematic review of one randomized, double blind, placebo controlled 
clinical trial, one randomized, non-blinded, placebo controlled clinical trial, and one case 
controlled non-randomized, non-blinded prospective pilot trial between 2009-2019, all written in 
English language and peer reviewed.  
 
DATA SOURCES: The randomized, double blind, placebo controlled clinical trial was found 
using PubMed. The randomized, non-blinded, placebo controlled clinical trial and case-
controlled pilot study were found on Embase.  
 
OUTCOME MEASURED: The outcome measured was the neurodevelopmental skills. The 
neurodevelopment of gross motor skills was measured at 9 months of age utilizing the Gesell 
developmental scale, neurodevelopment of mobility at 12 months of age using a WIDEA scale 
parental questionnaire, and the Denver Developmental Screening Test II evaluating gross motor 
skills, fine motor skills, language and personal social skills.  
 
RESULTS: The study conducted by Wu et al.2  evaluated mobility and showed a mean of 28.6 
with a SD of 3.8 for the erythropoietin treated group and a mean of 23.8 with a SD of 8.9 for the 
placebo group, with a P value of .048 showing a significant difference in the erythropoietin 
treated group. Additionally, the pilot trial conducted by Elmahdy et al.8 had a significant 
treatment effect in the erythropoietin treated group with a NNT of -2, a large treatment effect at 
preventing an abnormal Denver Developmental score. However, the study conducted by Lv et 
al.5 showed a P value of > 0.05 showing an insignificant treatment effect.   
 
CONCLUSIONS: The studies used in this review suggests that erythropoietin may be useful as 
an adjunctive treatment in preventing poor neurodevelopmental outcomes in neonates with 
hypoxic ischemic encephalopathy. However, the data is inconsistent between the three studies as 
two of them showed clinical significance and one did not. Due to the limitations of the studies 
such as small sample size and lack of long-term evidence of clinical significance with 
erythropoietin, further research is warranted.  
 
KEY WORDS: Neonatal hypoxic ischemic encephalopathy AND erythropoietin, asphyxia   
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INTRODUCTION 
 
Neonatal hypoxic ischemic encephalopathy (HIE) is a significant brain injury that is due 
to a lack of adequate blood flow and oxygen to the brain, either in utero or at birth, and may 
result in a range of neurodevelopmental deficits or death. Neonatal encephalopathy is described 
by American College of Gynecology as “disturbed neurologic dysfunction in early days of life in 
an infant born at or beyond 35 weeks’ gestation”.1 Clinical signs of HIE include a low Apgar 
score, low cord pH, neonatal seizures and encephalopathy.1 Trials show that even with the 
standard treatment of therapeutic hypothermia, more than 40% of infants with HIE suffer with 
neurodevelopmental disability or death.2 Due to the increased incidence of death and disability, 
neuroprotective agents have been researched in search for additional HIE therapies.2  
HIE may be a result of ischemia such as insufficient of blood flow to organs, or from 
insufficient oxygen inspiration or carrying capacity.1 Fetal HIE can occur due to impaired 
oxygenation in the mother, inadequate placental perfusion or placental pathology, or impaired 
fetal oxygenation.1 HIE can also occur in the perinatal period due to prolonged labor, umbilical 
cord problems, and shoulder dystocias.3 The cascade of events in an ischemic or hypoxic injury 
leads to impairment of the removal of metabolic and respiratory products such as lactic acid and 
carbon dioxide.1 The result of HIE is neuronal injury from energy failure and loss of 
mitochondrial function.1 Additionally, there is membrane depolarization, brain edema, increase 
neurotransmitters and intracellular calcium which results in cascades and oxidative stress.1  
Currently, the only therapy proven to improve outcomes in neonates with HIE is 
hypothermia. However, this therapy has only shown improvement in neonates classified with 
moderate to severe HIE, rather than more mild degrees of hypoxia or ischemia. The severity is 
typically defined using the Sarnat exam which evaluates level of consciousness, spontaneous 
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activity, tone, posture, primitive reflexes and autonomic function.4 Erythropoietin is a 
neuroprotective agent currently being studied for its prevention of further brain injury and 
improvement in neurodevelopmental outcomes.1 Erythropoietin is a glycoprotein found in the 
liver of fetuses. The function of erythropoietin is to stimulate bone marrow hematopoietic stem 
cells thus promoting proliferation, differentiation and maturation of red blood cells to upregulate 
oxygenation in the body.5 Erythropoietin receptors are expressed in the developing CNS, 
proposing neuroprotective effects.6 The mechanism behind erythropoietin’s protection of nerves 
is not fully understood at this time. It is unknown whether the use of erythropoietin in neonates 
with HIE will prevent long-term complications in neonates born with HIE.  
Incidence of neonatal HIE is estimated to be 1.5 per 1000 live births and contributes to 
23% of neonatal deaths.4 It is difficult to determine the exact number of healthcare visits as a 
result of HIE. However, there is a spectrum of long-term outcomes in neonates born with HIE. 
Physician Assistants may have the opportunity to treat these newborns immediately after birth in 
the NICU. PA’s also may encounter patients with consequences of HIE throughout the lifespan.  
The exact cost for neonatal HIE has not been identified. However, neonates with HIE 
may have neurodevelopmental disorders leading to financial burden for medical expenses and 
social services to meet the child’s need. The cost of EPO injections in the US is stated to be 
$39.79 for 2000 units/mL for Epogen, $64.15 for 2000 units/mL of Procrit and $26.47 for 
2000units/mL of Retacrit.7 It is important to note that treatment of neonatal HIE with 
erythropoietin requires more than one dose and it is typically considered a high dose to allow the 
drug to penetrate the blood brain barrier. Additionally, the drug is dosed for neonates using 
IU/kg. It is known that erythropoietin is widely available and easily administered.2 This paper 
will discuss three studies that evaluate the efficacy of erythropoietin in neonates with HIE.  
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Objective 
The objective of this selective EBM review is to determine whether or not erythropoietin 
is effective in preventing neurodevelopmental symptoms in neonates with hypoxic ischemic 
encephalopathy (HIE).  
Method 
 One randomized blinded control study, one randomized non-blinded control study and 
one case control pilot trial were used in this review. Populations in each study were full term 
neonates with HIE. Neonates who received IV or IM erythropoietin injections were compared to 
control groups who received similar treatment, with the exception of erythropoietin. The 
outcome measured was neurodevelopment of gross motor skills at 9 months of age using the 
Gesell developmental scale,5 mobility at 12 months of age using a WIDEA scale parental 
questionnaire,2 and the Denver Developmental Screening Test II (DDST II) at 6 months.8 The 
Denver Developmental Screening Test II evaluated gross motor, fine motor, language and 
personal social skills.8  
Wu et al. conducted a randomized, double-blinded trial comparing short-term neurologic 
outcomes in neonates given erythropoietin and hypothermia to those given hypothermia alone.2 
This study was done by administering 1000U/kg of intravenous erythropoietin or a placebo on 
days 1,2,3, 5, and 7 days of age.2 The participants were then assessed at 12 months of age using 
the Warner Initial Developmental Evaluation (WIDEA). The WIDEA scale evaluated infant 
development of self-care, mobility, communication, and social recognition. This EBM review in 
particular evaluates the neurodevelopment of mobility in order to make a more accurate 
comparison to the Lv et al.’s RCT evaluation of gross motor skills. The Alberta Infant Motor 
Scale (AIMS) objectively rates motor function, however it is not reviewed in this paper.2  
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Lv et al. conducted a randomized, non-blinded trial comparing short-term neurologic 
outcomes in neonates given erythropoietin in addition to hypothermia versus those given 
hypothermia alone. The group that received erythropoietin were given 200IU/kg intravenous 
rhEPO, once a day, for ten days.5 The Gesell developmental scale (GDS), which evaluates gross 
motor, fine motor, adaptability, language and personal social skills was performed at 9 months of 
age.5 This review in particular evaluates the outcome of gross motor skills.   
Elmahdy et al. conducted a prospective case-control study. This was non-randomized and 
non-blinded, consisting of a normal healthy group, a control group and an erythropoietin group.8 
The erythropoietin group received 2500IU/kg subcutaneous human recombinant erythropoietin 
daily for 5 days.8 The study states the both the EPO group and the control group received similar 
care with the exception of the administration of EPO. The study does not state whether or not 
they utilized standard therapeutic hypothermia. This trial evaluates neurodevelopmental with the 
DDST II at 6 months of age. The outcome was reported as the number of abnormal DDST II.8  
The studies were found using PubMed and Embase. The keywords used were neonatal 
hypoxic ischemic encephalopathy, erythropoietin and asphyxia. All articles were written in the 
English language. Articles were selected if the study included patient-oriented outcomes and if 
the study was relevant to the clinical question. The articles were published between 2009-2019. 
The statistics reported in these articles were P-values, number needed to treat, and mean change 
from baseline with standard deviation. Table 1 shows the demographics and characteristics.  
Outcomes Measured  
The outcomes measured in each study evaluated neurodevelopmental symptoms in 
neonates with HIE, which is a POEM. The three studies evaluated outcomes ranging from 6-12 
months of age. For two studies, mobility and gross motor skills between the EPO and control 
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groups was evaluated in order to have a more consistent comparison when evaluating the 
effectiveness. The third study reported the number of infants with an abnormal DDST II. 
Table 1- Demographics & Characteristics of included studies 
Study  Type  # 
Pts  
Age  Inclusion 
Criteria  
Exclusion 
Criteria  
W
/
D 
Interventions 
 
Wu2 
(2016) 
RCT 50 Newborns  
>/=36 wks 
>/=36 wks 
gestation, 
hypothermia, 
initiated by 6hrs 
of age, perinatal 
depression,Apg
ar <5, 
CPR/ventilation
,pH <7 or base 
deficit >/= 15 in 
cord w/in 60 
min of birth, 
mod-severe 
encephalopathy  
Age at time 
of consent 
>23.5hrs, 
congenital 
anomalies, 
birth weight 
<1800g, head 
circumferenc
e <2SDs 
below mean, 
no 
indwelling 
line, no f/u 
9 Erythropoietin 
1000 U/kg IV 
days 1, 2, 3, 5, 7. 
First dose given 
as soon as 
possible up to 24 
hours of age  
All groups 
standard care of 
hypothermia/bod
y cooling 
Lv5 
(2017) 
RCT 42 Newborns 
>/=37wks  
Mod-severe 
HIE, >/=37wks 
gestation, 
>/=2500g, 
severe asphyxia 
at birth, Apgar 
score </=3 at 
1min or </=5 at 
5min, umbilical 
artery pH <7, 
abnormal neuro 
signs in first 
24hrs  
ICH, 
congenital 
malformation 
,infectious 
disease, 
maternal 
drug abuse, 
Hgb 
<120g/L, 
treatment 
refusal 
1 Epo IV 200 
IU/kg once daily 
for ten days  
All groups 
standard of care 
of 
hypothermia/bod
y cooling  
Elmahdy8 
(2010)  
Pilot 
trial 
Case 
Control 
 
45 
 
Newborns 
>/=38wks 
Term infant >38 
weeks, 
APGARR </=3 
at 5 min or 
delayed 1st 
breath, 
metabolic or 
mixed acidosis, 
evidence of 
encephalopathy  
Twins, 
maternal 
DM, 
congenital 
malformation
s of CNS, 
infections, 
IUGR 
1 Within 4-6hrs 
given EPO 
2500IU/kg for 5 
doses  
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Results  
 This review assesses whether or not erythropoietin is effective at preventing 
neurodevelopmental symptoms in neonates born with hypoxic ischemic encephalopathy. Studies 
conducted by Wu et al. and Lv et al. were continuous and could not be converted to dichotomous 
form. The study conducted by Elmahdy et al. was presented as dichotomous data.  
 Wu et al. conducted a study to determine if erythropoietin in addition to therapeutic 
hypothermia was effective at improving neurodevelopmental symptoms in neonates with HIE. 
This phase II, double-blinded randomized clinical trial included 50 newborns with HIE. Of the 
50 newborns included in the study, 2 were lost to follow up and 7 died before hospital 
discharge.2 All of the infants in the study had moderate-severe HIE based on the Sarnat scoring 
system and present at 1 to 6 hours of age.2 Further inclusion and exclusion criteria for the study 
can be found in Table 1. Newborns were randomly assigned to either the control group or 
erythropoietin group. The group receiving erythropoietin received 1000U/kg IV on days 1,2,3,5 
and 7. The control group received an equal amount of normal saline on the same days. The 
paired t-test used in the trial indicated that the two groups had an insignificant difference at 6 
months of age. However, the EPO group had a statistically significant difference in mobility by 
12 months of age (P<0.05) (Table 2).2  
Table 2- WIDEA mobility score at 6 months and 12 months of age expressed as mean ± SD2  
 EPO group Control group P-value  
6 mos. of age 14.1 (2.7) 12.4 (2.7) 0.06 
12 mos. of age  28.6 (3.8) 23.8 (8.9) 0.048* 
*= Statistically significant (P<0.05)                                                                         
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Lv et al. conducted a randomized, non-blinded, clinical trial on newborns with HIE to 
evaluate the effectiveness of erythropoietin in improving neonatal HIE treatment.5 Forty-two 
patients were involved in the study, initially. One patient from the control group was transferred 
to another hospital without mention of a worst-case analysis in the statistical data.5 Neonatal HIE 
was assessed using the Sarnat score to diagnose moderate and severe HIE.5 Further inclusion and 
exclusion criteria for the study can be found in Table 1. The EPO group was given 200 IU/kg of 
IV erythropoietin, once a day, for 10 consecutive days, in addition to conservative treatment.5 
The control group received hypothermia alone.5 Supportive care measures and hypothermia were 
the same between both groups.5 This study additionally evaluated a serum protein, an indicator of 
brain injury, which is not addressed in this review. The Gesell developmental scale (GDS) was 
then used at 9 months of age to assess neurodevelopment. The data for neurodevelopment in this 
study was expressed as mean with a percentage. Additionally, this data was presented as “good 
neurodevelopment”, “boundary situation”, and “neurodevelopmental retardation”. This review 
assesses gross motor development, in particular. The trial states that their results were clinically 
insignificant with a P-value of >0.05 (Table 3).5  
Table 3- Gross motor development at 9 months of age by Gesell’s assessment5  
Group Outcome Score as mean and % P-value 
Control Good  10 (50%) >0.05 
 Boundary situation 4 (20%) >0.05 
 Retardation  6 (30%) >0.05 
EPO Good  11 (52.3%) >0.05 
 Boundary situation 6 (28.6%) >0.05 
 Retardation 4 (19.1%) >0.05 
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The results of the trial conducted by Lv et al. indicate that erythropoietin is not effective at 
preventing neurodevelopmental symtpoms.5 
Elmahdy et al. conducted a prospective case-controlled pilot trial to evaluate the 
effectiveness of erythropoietin in asphyxia neonatorum (HIE). The patients had a full assessment 
at enrollment of the study and the severity of HIE was graded according to the Sarnat scale. 
Further inclusion and exclusion criteria can be found in Table 1. Forty-five patients were 
included in the study to make 3 groups. The study included a normal healthy group, an HIE 
erythropoietin group, and HIE-control group. Each group consisted of 15 patients. The HIE 
groups received similar care with the exception of administration of five doses of 2500 IU/kg 
erythropoietin for the HIE- erythropoietin group.8 At six months of age, 29 patients out of the 30 
patients in the HIE groups survived to complete the clinical evaluation.8 In this trial, neurologic 
outcomes were measured using the Denver Developmental Screening Test II (DDST II). This 
study evaluated all aspects of neurodevelopment as a whole, rather than breaking the DDST II 
results into individual scores for gross motor, language, fine motor and personal social. 
Additionally, results were recorded as death or an abnormal DDST II. The erythropoietin group 
showed a significant treatment effect with EPO when evaluating the patients with abnormal 
DDST II (P<0.05). Treatment effect was also measured using Number Needed to Treat (NNT). 
The calculations for NNT indicated a large treatment effect in using erythropoietin to prevent an 
abnormal DDST II (Table 5). One patient died from the control group and zero patients died 
from the EPO group, indicating no significant difference in number of deaths between the two 
groups.  
Table 4- Abnormal DDST II in EPO- HIE group and HIE- control group8 
Outcome EPO group Control group P-value 
Abnormal DDST II 4 (27%) 10 (71%) 0.03* 
*=Statistically significant (P<0.05) 
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Table 5- Calculations for Treatment Effect8 
 CER EER RRR ARR NNT 
Abnormal 
DDST II 
Prevention 
0.71 0.27 -0.62 -0.44 -2  
 
Discussion 
 Neonatal HIE causes significant ischemic brain injury that can result in a range of mild to 
severe neurodevelopmental symptoms, and even death. Although the standard therapeutic 
hypothermia is found to be an effective treatment, many neonates still suffer long-term sequela 
of a hypoxic brain injury, indicating the need for a neuroprotective agent such as erythropoietin. 
Erythropoietin is a cytokine that has shown neuroprotective effects on the brain.2 These trials 
sought to evaluate the efficacy of erythropoietin as a potential agent to treat HIE. It is important 
to note that this treatment has a high safety profile. EPO is also used for anemia of prematurity, 
with a warning for risk of retinopathy of prematurity.7  
One concern for all three studies was that they only evaluate the short-term outcomes of 
erythropoietin. Neonatal HIE causes a wide range of neurodevelopmental symptoms, requiring 
further evaluation of long-term development with the use of erythropoietin. Further evaluation of 
these infants throughout their development would provide more evidence in the use of 
erythropoietin for prevention of neurodevelopmental symptoms or delay. Additionally, these 
studies did not mention the level of care that the subjects received between birth and follow up. 
For instance, those receiving PT, OT, Speech therapy may have different neurodevelopmental 
symptoms than those who did not receive these therapies. The intent of this EBM review was to 
evaluate the efficacy of erythropoietin as a neuroprotective agent in neonates with HIE. 
However, after evaluation of neurodevelopmental outcomes in the three articles reviewed, the 
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answer is still unclear whether or not erythropoietin is effective at preventing 
neurodevelopmental symptoms after a hypoxic brain injury. As two studies did report efficacy in 
the use of erythropoietin, one study did not. Additionally, these studies reported significant 
difference between groups in some areas of development, but insignificant difference in other 
areas. The various areas of development throughout the lifespan may provide a challenge in 
determining prevention of neurodevelopmental symptoms.  Limitations of all three studies 
include the small sample sizes, lack of long-term follow up of further neurodevelopmental 
stages, and including only moderate to severe HIE. It is important to note that these studies do 
not evaluate the use of erythropoietin in mild HIE.  
 Wu et al.’s RCT established a significant difference in neonates treated with 
erythropoietin over those receiving the placebo when evaluating infants at 12 months of age.2 
However, this EBM review only takes mobility into consideration to allow a better comparison 
to the other articles chosen for this review. When evaluating the total WIDEA score, results are 
clinically insignificant between the erythropoietin group and control group.2 Additionally, the 
WIDEA score is a parental questionnaire, which could potentially lead to inaccurate or biased 
report of their child’s development.  
 Lv et al.’s RCT did not establish a statistical significance in gross motor skills at 9 
months of age in those treated with erythropoietin therapy.5 However, it is important to note that 
this trial used a much lower dosage of erythropoietin than the other trials in this EBM review. 
Additionally, enrollment into the NICU ranged from 2014 to 2015 during the trial, which could 
potentially alter results based on varied clinical judgement and treatment plans from different 
physicians caring for the neonate. This trial was also randomized based on order of admission 
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and participants in the study were not blinded. Although the trial was not blinded, outcomes were 
measured objectively using a Gesell developmental scale and raters were blinded.5  
 Elmahdy et al.’s prospective case control trial established a significant difference in 
neurodevelopmental symptoms in those treated with erythropoietin versus those in the control 
group.8 The short time to follow up could affect the outcome as six months of age is relatively 
early in development to determine delays or neurodevelopmental symptoms. This article 
additionally does not state the care plan for the patient with the exception of those receiving 
erythropoietin. Lastly, this study is limited by a small sample size of 15 subjects.  
Conclusion 
 While some trials do look promising with administration of EPO in neonates with HIE, 
the data is still inconclusive. While Wu et al. and Elmahdy et al. established statistical 
significance, Lv et al. failed to establish a statistical difference. A major factor in determining the 
efficacy depends on more long-term data on neurodevelopmental outcomes to determine how 
effective the treatment is, later in development. Additionally, this EBM review evaluates sub-
scores of neurodevelopmental scales. It is important to note that neurodevelopment entails many 
aspects of developmental milestones. The outcomes provided in this EBM review imply that 
additional studies need to be performed, with more long-term neurodevelopment results and a 
larger sample size. The use of a standard dose and evaluation at various developmental 
milestones may be useful in further studies. Although the standard treatment of hypothermia has 
showed improvements in those born with HIE, disability and death still occur even in the 
highest-level care NICU’s. Further exploration of erythropoietin, a neuroprotective agent, is 
needed to determine the benefit of the therapy.
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